Navigation Links
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Date:12/20/2010

60;There were six deaths (3.4%) among the 175 patients treated with VEGF Trap-Eye and one (2.3%) in the 44 patients treated with laser over 12 months.

Detailed results for DA VINCI will be presented at the Angiogenesis Conference in Miami, Florida in February 2011.

About the Phase 3 CRVO Program Patients in the COPERNICUS (Controlled Phase 3 Evaluation of Repeated intravitreal administration of VEGF Trap-Eye In Central retinal vein occlusion: Utility and Safety) and the identical GALILEO (General Assessment Limiting Infiltration of Exudates in central retinal vein Occlusion with VEGF Trap-Eye) studies receive six monthly injections of either VEGF Trap-Eye at a dose of 2mg or sham injections.  Patients in the COPERNICUS trial were randomized in a 3:2 ratio with 114 patients randomized to receive VEGF Trap-Eye and 73 randomized to the control arm.  At the end of the initial six months, all patients randomized to VEGF Trap-Eye are dosed on a PRN (as needed) basis for another six months.  In the COPERNICUS trial, patients randomized to sham injections in the first six months are eligible to cross over to VEGF Trap-Eye PRN dosing in the second six months.  During the second six months of the studies, all patients are eligible for rescue laser treatment.  Visual acuity was measured as a score based on the total number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart, a standard chart used in research to measure visual acuity.  

About Central Retinal Vein Occlusion (CRVO)Over 100,000 people in the United States and more than 66,000 people in key European countries are estimated to suffer from CRVO.  CRVO is caused by obstruction of the central retinal vein that leads to a back up of blood and fluid in the retina.  This causes retinal injury and loss of vision.  The retina can also become "ischemic" (starved for oxygen), resulting in the growth of new
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), a ... for all forms of sports, including extreme motor sports, ... announced today that the UISP Lega Motociclismo Lombardia, an ... riders to wear a neck brace during its racing ...
(Date:1/23/2015)... 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... development and sale of patented biopharmaceutical medicine, modernized traditional ... (API) today announced the business and development progress at ... 1. Following the September 2014 JCM application (No. 51268) ...
(Date:1/22/2015)... ON , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. ... with a focus on Omega-3 therapies for cardiovascular disease and ... of the Company,s accomplishments in 2014 and its outlook for ... Dear Fellow Shareholders, We would like to ...
Breaking Medicine Technology:Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... , STAMFORD, Conn., Nov. 13 ... it will be releasing a free trial version of its ... Sessions conference, taking place this November 15-17 in Orlando. Zargis ... of the companion hardware -- the 3M Littmann Electronic Stethoscope ...
... , , SILVER SPRING, Md., ... today approved Lysteda tablets (tranexamic acid), the first non-hormonal ... works by stabilizing a protein that helps blood to ... ) , Heavy menstrual bleeding is reported each year ...
Cached Medicine Technology:Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference 2Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference 3FDA Approves Lysteda to Treat Heavy Menstrual Bleeding 2
(Date:1/22/2015)... January 23, 2015 The U.S. Pharmacopeial ... DICVP, Director of Clinical Pharmacy Services at North Carolina ... recipient of the 2015 Beal Award for Distinguished Volunteer ... has relied on the contributions of volunteer experts to ...
(Date:1/22/2015)... January 22, 2015 The City of West Hollywood ... a.m., to commemorate the 42nd anniversary of the Supreme Court decision ... “It’s been 42 years since the Roe vs. Wade decision and ... as present as ever,” said City of West Hollywood Councilmember Abbe ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, AZ has ... (PPHA). The PPHA's passion for others' well-being and shared ... treated for obstructive sleep apnea (OSA) has propelled them into ... the valley. The most recent plans for an event will ...
(Date:1/22/2015)... 23, 2015 Angelweddingdress is a famous wedding ... its customers to follow it on Facebook, Twitter, and Pinterest. ... Day gift. Angelweddingdress draws a lottery every week. , Moreover, ... Feb. 28, 2015. Click Angelweddingdress homepage for more ...
(Date:1/22/2015)... The federal court overseeing thousands of vaginal ... Southern District of West Virginia has upheld a $2 million ... bellwether trial. In an Order dated January 21st, the Court ... that C.R. Bard had not proven a miscarriage of justice. ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... Now! Coalition applauds the House,s important decision to allocate ... American Recovery and Reinvestment Act for incentives to promote ... this outcome," Joel White, executive director of the Coalition ... coalition has advocated for legislation with significant funding provisions ...
... Jan. 29, 2009 Mice whose fat cells were allowed to ... when fed a high-fat diet, researchers at UT Southwestern Medical Center ... mice lacked a protein called collagen VI, which normally surrounds fat ... around a water balloon. The findings appear online and in a ...
... that exercise may be a factor in recovering from ... and knee osteoarthritis (OA). One study involving a progressive ... it enhanced clinical improvement almost to the level of ... examine the relationship between four components of physical activity ...
... (OA) causes disability and is a major public health ... 4 and 6 sulfate (CS) on OA progression and ... dietary supplements in the U.S., has been approved as ... many European countries. The study was published in the ...
... North State Bancorp (OTC,Bulletin Board: NSBC) (the "Company"), the ... $687.6 million as of December 31, 2008,compared to total ... increase,of $140.1 million or 25.6%. , ... 31, 2008 were $612.7,million and total loans were $546.4 ...
... smoking laws make it this year,s worst city for asthmatics, ... Louis is now the 2009 "Asthma Capital of the United ... annual ranking of the 100 most challenging places to live ... 2008, St. Louis went to the top of this year,s ...
Cached Medicine News:Health News:UT Southwestern researchers identify protein that may explain 'healthy' obesity 2Health News:Exercise plays large role in recovery from knee replacement and the occurrence of osteoarthritis 2Health News:Exercise plays large role in recovery from knee replacement and the occurrence of osteoarthritis 3Health News:Chondroitin slows progression and relieves symptoms of knee osteoarthritis 2Health News:North State Bancorp Reports Profitable 2008 2Health News:North State Bancorp Reports Profitable 2008 3Health News:North State Bancorp Reports Profitable 2008 4Health News:North State Bancorp Reports Profitable 2008 5Health News:North State Bancorp Reports Profitable 2008 6Health News:St. Louis Ranked America's 'Asthma Capital' 2
... The EBV laboratory diagnosis is generally confirmed ... Severity of the disease however, is not indicated ... IM occurs in 10 - 20 percent of ... EBV are necessary to fully ascertain the stage ...
... IDI-Strep B test can lower healthcare costs ... hospital stays. By identifying mothers colonized with ... more targeted and effective antibiotic prophylaxis. This ... of infants and reduce unnecessary antibiotic use ...
... Needle is specially designed to help you ... reliable core sample. All needles are engineered ... polished surfaces for smooth entry and exit. ... needle sizes assures an ideal match with ...
... Used to obtain multiple core biopsies of ... Biopsy Needle design facilitates one-handed control. Precise, ... sample. Beveled point stylet permits easy penetration ... surrounding tissue. Sharp cutting edge of cannula ...
Medicine Products: